Skip to main content
BIO
NYSE Industrial Applications And Services

Bio-Rad 10-Q Details Q3: $458.6M GAAP Profit Is a Sartorius Mark; Operations Lost $49.7M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$379.29
Mkt Cap
$10.188B
52W Low
$236.73
52W High
$396.23
52W Position info
60% above low
Off High info
4.3% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

BIO sits 60% above its 52-week low of $236.73.

Summary

Bio-Rad's Q3 GAAP profit of $458.6 million was almost entirely a non-cash Sartorius mark-to-market gain; core operations lost $49.7 million after $77.2 million of restructuring and a $49.8 million Celsee impairment, on flat sales of $656.4 million.


Key Events · Earnings and Guidance · BIO

  • Q3 Sales Flat at $656.4M

    Net sales rose 0.5% reported and 0.7% currency-neutral versus $653.0 million. Clinical Diagnostics grew 2.7% to $401.8 million while Life Science fell 2.8% to $254.6 million.

  • GAAP Profit Is a Sartorius Mark

    GAAP net income of $458.6 million ($17.02 per diluted share) came from a $588.2 million non-cash gain on equity securities. GAAP operations lost $(49.7) million after $77.2 million of restructuring and a $49.8 million intangible impairment.

  • July Restructuring Costs $77.6M in Q3

    The July 2026 plan carries $80 million to $90 million of expected pre-tax cost and is targeted to cut annual operating expenses by $30 million to $35 million by the end of 2027, with completion expected by then.

  • Celsee Technology Written to Zero

    Bio-Rad cut R&D and marketing on single-cell products from the 2020 Celsee deal and recorded a $49.8 million impairment in the Life Science segment, reducing the developed technology's carrying value to zero.


Analysis · BIO · Industrial Applications And Services

The headline profit is accounting, not operations. Bio-Rad's $458.6 million of Q3 GAAP net income rests on a $588.2 million non-cash gain from marking up its Sartorius stake — a paper entry that reverses with the share price and involves no cash. Strip that out and the core business lost $(49.7) million from operations after $77.2 million of restructuring charges and a $49.8 million write-off of the Celsee single-cell technology, which the company has effectively abandoned. Sales were essentially flat at $656.4 million, with Clinical Diagnostics up 2.7% offsetting a 2.8% decline in Life Science. The offsetting item is the July 2026 restructuring: $80-90 million of total cost for $30-35 million of annual savings by the end of 2027, a real margin lever but one that keeps charges flowing through 2027. Cash generation slipped to $303.2 million for nine months from $367.3 million, and the $400 million of 3.3% notes now sit in current liabilities ahead of their March 2027 maturity — comfortably covered by $1.66 billion of cash and short-term investments.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BIO was trading at $379.29 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $236.73 to $396.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BIO - Latest Insights

BIO
Nov 04, 2026, 5:15 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $379.29
Real-time Price: $358.90 info
Change: -$20.39 (-5%) info
Market Cap: $9.693B info
BIO
Nov 04, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $379.29
Real-time Price: $358.90 info
Change: -$20.39 (-5%) info
Market Cap: $9.693B info
BIO
Aug 04, 2026, 5:42 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $326.33
Real-time Price: $358.90 info
Change: +$32.57 (+10%) info
Market Cap: $9.693B info
BIO
Aug 04, 2026, 4:27 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $326.33
Real-time Price: $358.90 info
Change: +$32.57 (+10%) info
Market Cap: $9.693B info
BIO
Aug 04, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $326.33
Real-time Price: $358.90 info
Change: +$32.57 (+10%) info
Market Cap: $9.693B info